drugset
drugset / Trial / NCT03990896

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

NCT03990896 ↗

Phase 2 Recruiting 30 enrolled Massachusetts General Hospital Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.

Timeline

Start
2021-11-18
Primary completion
2027-03-31
Completion
2028-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Talazoparib Small molecule — Oral

Indications

breast cancer